학술논문

Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells
Document Type
article
Source
Leukemia. 31(6)
Subject
Genetics
Pediatric Cancer
Pediatric
Hematology
Rare Diseases
Cancer
Childhood Leukemia
Obesity
2.1 Biological and endogenous factors
Aetiology
Animals
Apoptosis
Cell Proliferation
DNA (Cytosine-5-)-Methyltransferases
DNA Methylation
Diet
High-Fat
Fatty Acid-Binding Proteins
Gene Expression Regulation
Neoplastic
Humans
Interleukin-6
Leukemia
Myeloid
Acute
Mice
Mice
Inbred C57BL
STAT3 Transcription Factor
Tumor Cells
Cultured
Clinical Sciences
Oncology and Carcinogenesis
Immunology
Language
Abstract
Obesity is becoming more prevalent worldwide and is a major risk factor for cancer development. Acute myeloid leukemia (AML), the most common acute leukemia in adults, remains a frequently fatal disease. Here we investigated the molecular mechanisms by which obesity favors AML growth and uncovered the fatty acid-binding protein 4 (FABP4) and DNA methyltransferase 1 (DNMT1) regulatory axis that mediates aggressive AML in obesity. We showed that leukemia burden was much higher in high-fat diet-induced obese mice, which had higher levels of FABP4 and interleukin (IL)-6 in the sera. Upregulation of environmental and cellular FABP4 accelerated AML cell growth in both a cell-autonomous and cell-non-autonomous manner. Genetic disruption of FABP4 in AML cells or in mice blocked cell proliferation in vitro and induced leukemia regression in vivo. Mechanistic investigations showed that FABP4 upregulation increased IL-6 expression and signal transducer and activator of transcription factor 3 phosphorylation leading to DNMT1 overexpression and further silencing of the p15INK4B tumor-suppressor gene in AML cells. Conversely, FABP4 ablation reduced DNMT1-dependent DNA methylation and restored p15INK4B expression, thus conferring substantial protection against AML growth. Our findings reveal the FABP4/DNMT1 axis in the control of AML cell fate in obesity and suggest that interference with the FABP4/DNMT1 axis might be a new strategy to treat leukemia.